"Liver NETs: Understanding Liver-Directed Therapies and PRRT"

Some Topics Covered: Neuroendocrine tumors (NETs), liver metastases, liver-directed therapies, peptide receptor radionuclide therapy (PRRT), NET treatment, neuroendocrine cancer

ABOUT

Join us for an overview of liver-directed therapies and peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors involving the liver. Presented by a physician with expertise in both interventional radiology and nuclear medicine, this webinar will explore how treatment decisions are made, when different approaches may be considered, and how these therapies may fit into an overall treatment plan.

ASK YOUR QUESTIONS

Submit your broad-based, general questions for Dr. Fine to answer during the live Q&A.

ABOUT DR. GABRIEL FINE

Gabriel Fine, M.D.

Interventional & Nuclear Medicine Radiologist

Nuclear Medicine

City of Hope Cancer Center Duarte, California

Gabriel Fine, M.D., is an associate professor of diagnostic radiology at City of Hope® Cancer Center Duarte, California, with a focus on theranostics and nuclear medicine. Dr. Fine combines expertise in minimally invasive radiological techniques with a compassionate, personalized approach to care, harnessing the power of precision diagnostic imaging and therapeutics to combat cancer.

From a young age, Dr. Fine was surrounded by people who dedicated their lives to helping others. After earning his medical degree at the University of Washington School of Medicine in Seattle, Dr. Fine decided to specialize in radiology, pursuing a residency in diagnostic radiology at the University of Washington and an interventional radiology fellowship at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Fine is triple board-certified in diagnostic, interventional and nuclear radiology and has co-authored more than a dozen publications. He has received several honors, including a Sarnoff Cardiovascular Research Foundation Fellowship and membership in the Sigma Xi Scientific Research Society, and is an anonymous stem cell donor who has contributed to the survival of two leukemia patients.

 THANKS TO OUR SPONSORS

The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.